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We recently reported that differential gene expression and DNA methylation profiles in blood 
leukocytes of apparently healthy smokers predicts with remarkable efficiency diseases and conditions 
known to be causally associated with smoking, suggesting that blood-based omic profiling of human 
populations may be useful for linking environmental exposures to potential health effects. Here 
we report on the sex-specific effects of tobacco smoking on transcriptomic and epigenetic features 
derived from genome-wide profiling in white blood cells, identifying 26 expression probes and 92 
CpG sites, almost all of which are affected only in female smokers. Strikingly, these features relate to 
numerous genes with a key role in the pathogenesis of cardiovascular disease, especially thrombin 
signaling, including the thrombin receptors on platelets F2R (coagulation factor II (thrombin) receptor; 
PAR1) and GP5 (glycoprotein 5), as well as HMOX1 (haem oxygenase 1) and BCL2L1 (BCL2-like 1) 
which are involved in protection against oxidative stress and apoptosis, respectively. These results 
are in concordance with epidemiological evidence of higher female susceptibility to tobacco-induced 
cardiovascular disease and underline the potential of blood-based omic profiling in hazard and risk 
assessment.
Exposure to tobacco smoke is one of the best studied examples of an exposure with proven causal association with 
a large number of human diseases1. Although the relevant epidemiological evidence is not completely consistent, 
many studies have provided evidence of differential sex susceptibility to the health effects of tobacco, especially in 
relation to smoking-induced cardiovascular disease (CVD; including acute myocardial infarction and coronary 
heart disease)2–4, chronic obstructive pulmonary disease (COPD)1,5,6 and lung cancer7–9. Focusing in particular 
on CVD, a systematic review and meta-analysis of data from 86 prospective studies and nearly 4 million subjects 
came to the conclusion that female smokers have a 25% higher risk of developing coronary heart disease than 
males with the same exposure to tobacco smoke and after allowing for other risk factors2, a conclusion supported 
by the results of a recent meta-analysis of the available data3. Another recent systematic review and meta-analysis 
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covering data from 81 cohorts and nearly 4 million subjects concluded that the risk of stroke in Western popula-
tions is 10% higher in female smokers4.
Biomarker-based investigations have contributed significantly to our understanding of the disease risks 
associated with exposure to environmental hazards. Currently such biomarker studies are benefiting from the 
expanding use of genome-wide profiling (omics). We have recently reported the results of a study of the impact 
of tobacco smoke exposure on genome-wide gene expression and DNA methylation in white blood cells (WBCs) 
of apparently healthy smokers10 and identified large numbers of transcripts and DNA CpG sites whose expres-
sion and methylation, respectively, differ significantly between current and never smokers. Furthermore we used 
disease connectivity analysis to show that the corresponding gene profiles can identify with remarkable efficiency 
(specificity 94%, positive predictive value 86%) most diseases and conditions independently known to be causally 
associated with smoking10. In view of this finding, we decided to look for sex-related differences in these profiles 
which might possibly reflect differential disease susceptibility.
Results
In order to minimise statistical power problems, we focused our search for sex-related differences in the effects of 
tobacco smoking on the transcriptomic and epigenetic features which we previously found to differ significantly 
between mixed-sex groups of current and never smokers10. These features consist of 1,273 CpG sites (FDR < 0.05; 
associated with 725 differentially methylated genes - DMGs) and 350 transcripts (FDR < 0.10; associated with 271 
differentially expressed genes - DEGs) which were derived from the comparison of genome-wide transcriptomic 
and epigenetic profiles of 143 current and 311 never smokers (including 134 males and 320 females) derived from 
2 cohorts, the Northern Sweden Health and Disease Study and EPIC Italy (Suppl. Tables S1 and S2).
The tobacco exposure data available to us (Table 1) included the number of cigarettes smoked per day and 
smoking duration in both cohorts, the smoking intensity measured in pack-years (only in the Italian cohort), as 
well as plasma cotinine levels for a fraction of the study subjects from both cohorts. Inspection of this data did not 
reveal statistically significant differences between the two sexes, although it did suggest possibly higher exposure 
intensity (pack-years) in males (Table 1). While the above parameters provide an approximate picture of smoking 
exposure, they do not allow an accurate quantitative estimation of the long-term exposure to tobacco smoke of 
the different subjects suitable for use in statistical adjustment for the purpose of sub-group comparison. For this 
reason, and also having in mind our previous observation of the highly skewed distribution of the expression or 
methylation differences between current and never smokers (effect size), we opted to base our sex comparisons 
not on the effect size, which is expected to be strongly dependent on exposure level and duration, but on the 
ranking of the various features by statistical significance (i.e. p-values in current vs never smoker comparisons) 
in sex-stratified analyses. Thus we compared the full set of signals separately for males and females, ranking them 
according to the statistical significance of their current-versus-never smoker differences in each sex and, finally, 
compared the rankings in the two sexes of the limited number of signals of interest. The methodology is described 
in detail in Methods while the workflow of the procedure is shown diagrammatically in Fig. 1. We adopted this 
Males Females
N 236 413
age; mean (range) 51.0 (30.2–65.0) 52.8(29.6–74.9)
cohort
NSHDS; N 171 228
EPIC Italy; N 65 185
BMI; mean (range) 26.5 (19.0–39.5) 25.4(18.8–55.28)
smoking status
current smokers; N 43 (18.2%) 100 (24.2%)
former smokers; N 102 (43.2%) 93 (22.5%)
never smokers; N 91 (38.6%) 220 (53.3%)
duration of smoking
N 40 90
years, mean (s.d) 31.8 (8.7) 30.6 (18.1)
p 0.49
pack-years*
N 14 45
mean (S.D) 582.9 (429.0) 356.6 (266.0)
p 0.06
cigarettes/day
total N 42 98
≤ 4, N 7 (16.7%) 24 (24.5%)
5–15, N 17 (40.5%) 50 (51%)
≥ 25, N 18 (42.9%) 24 (24.4%)
p# 0.2
plasma cotinine
N 40 35
AUC; mean (s.d.) 33.7 (8.7) 28.1 (8.5)
p 0.85
Table 1.  Study population and sex comparison of smoking exposure-related parameters. *Only EPIC Italy; 
#chi-squared test.
www.nature.com/scientificreports/
3Scientific RepoRts | 7:42870 | DOI: 10.1038/srep42870
approach on the reasonable assumption that any differences between the sexes with regard to the level or dura-
tion of exposure would in general affect the effect size for the different features in a similar manner but would be 
unlikely to alter their ranking within each sex group. This non-parametric approach has the added advantage that 
it minimizes the impact of non-normal data distribution, outliers and differences in statistical power arising from 
the different sizes of the male and female populations.
Suppl. Fig. S1 shows the distribution of the p-values of the rank differences in the two sexes. It can be seen that 
a biomodal distribution is observed, with the anticipated pattern of decreasing numbers of signals as p-values 
decrease being observed along with an increased number of signals with very low p-values (< 0.05) increases. The 
latter indicates the existence, among both the transcriptomic and the epigenetic signals, of sub-groups of signals 
whose ranking differences between the sexes are more significant than expected.
Tables 2 and 3 show the lists of expression probes and CpG sites, respectively, whose significance rankings dif-
fer significantly (p < 0.05) between the two sexes. There was no significant difference in the corresponding rank-
ings of these signals between male and female never smokers (results not shown), indicating that the observed 
sex-related differences reflect the differential impact of tobacco smoke exposure.
Expression profile. All 26 expression probes in Table 2 show large ranking differences between the sexes, 
with 23 exhibiting higher significance in females (median ranks: 111 in females and 19,775 in males), while 
the remaining 3 probes show higher significance in males. All probes are underexpressed in smokers with the 
exception of 2 which are overexpressed particularly in male smokers. Owing to population size limitations, many 
of the identified signals do not reach statistical significance in the sex-stratified analyses. However, for the 23 
female-specific probes, the median FDR value with regard to the current-versus-never smoker comparisons is 
0.40 (range 0.01–0.91) in females while all 23 have FDR > 0.80 in males (not shown), suggesting that the effects 
of smoking are largely limited to females. Importantly, as shown in Table 2 these significance ranking differences 
are accompanied by a corresponding difference in effect sizes for all the signals identified, with the median effect 
size (ratio of expression in current divided by never smokers) observed being 0.80 (range 0.72–0.93) and 0.96 
(range 0.93–1.00) in females and males, respectively. No expression probe shows opposite effects of smoking in 
the two sexes.
Figure 1. Workflow of the statistical analysis. 
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Epigenetic profile. Turning to the epigenetic profile, the 92 CpG sites (associated with 72 genes) thus iden-
tified (Table 3) show both under- and overmethylation in smokers while their ranking differences between the 
sexes are also substantial, with the median rank values being 432 and 215,917 in females and males, respectively. 
The median FDR value of these CpG sites is 0.12 (range 0.0002–0.68) in females, while all 92 sites have FDR > 0.9 
in males. In complete analogy to what is observed for the transcriptomic profile, for all CpG sites the impact of 
smoking (Δ β = β smokers − β non-smokers) is greater in females than in males, with the median absolute Δ β values being 
1.55% (range 0.15–8.45%) and 0.33% (range 0.00–8.45%), in females and males, respectively. No CpG sites exhibit 
opposite effects of smoking in the two sexes. There was no statistically significant overabundance in the distribu-
tion of the CpG sites in relation to their locations (TSS200, TSS1500, body, 3′ UTR, 5′ UTR, 1st exon, intragenic) 
or to their occurrence in CpG islands and their regions (island, non-island S-shore, S-shelf, N-shore, N-shelf). 
Finally, we note that one gene, PLIN5, appears to be more overexpressed in females but more undermethylated in 
males, implying a possibility of differential epigenetic regulation in the two sexes.
Consistency and stability of observed sex effects. Owing to the limited population size no direct rep-
lication between the two cohorts was conducted. However, cohort-stratified analyses show that the features listed 
in Tables 3 and 4 tend to be among the most significant features, in terms of sex differences, also in the individual 
cohorts. Thus, the median rank value of the 92 CpG sites of Table 4 was 3,048 (out of a total of 410,987 sites exam-
ined; top 0.7%) in females and 195,213 in males in NSHDS, and 9,098 (top 2%) and 218,704, respectively, in EPIC 
Italy, thus demonstrating a clear trend of higher female sensitivity in both cohorts. A similar trend was seen with 
the corresponding transcriptomic signals of Table 2, with the 23 female-specific signals having median ranks of 
585 (out of a total of 29,667 probes examined; top 2%) in females and 25,742 in males in NSHDS, and 1,708 (top 
Expression 
probe Gene symbol Gene name
Rank by p-value in sex-
stratified analysis
Effect size (ratio current/never 
smokers) in sex-stratified analysis
Males Females
p rank 
difference Males Females
A_23_P120883 NMOX1 heme oxygenase (decycling) 1 29,411 31 2.82E-05 1.00 0.77
A_23_P87013 TAGLN transgelin 29,013 74 3.86E-05 1.00 0.80
A_24_P410453 SYNE1 spectrin repeat containing. nuclear envelope 1 28,573 120 5.42E-05 1.00 0.81
A_23_P23834 LGR6 leucine-rich repeat-containing G protein-coupled receptor 6 27,005 26 1.46E-04 1.49 0.72
A_23_P136347 EPS8 epidermal growth factor receptor pathway substrate 8 26,954 16 1.50E-04 0.99 0.75
A_24_P173754 C1orf21 chromosome 1 open reading frame 21 24,586 24 6.54E-04 0.98 0.78
A_23_P354387 MYOF myoferlin 24,542 111 7.06E-04 0.98 0.79
A_23_P66881 RGS9 regulator of G-protein signaling 9 21,736 118 3.29E-03 0.96 0.79
A_24_P76644 20,804 121 5.24E-03 0.98 0.88
A_23_P86682 MYOF myoferlin 19,999 56 7.46E-03 0.96 0.78
A_23_P43679 ZNF618 zinc finger protein 618 19,852 22 7.86E-03 0.96 0.84
A_23_P1962 RARRES3 retinoic acid receptor responder (tazarotene induced) 3 19,775 113 8.49E-03 0.97 0.87
A_23_P113161 C1orf21 chromosome 1 open reading frame 21 19,632 47 8.80E-03 0.95 0.75
A_24_P921823 TCF7L2 transcription factor 7-like 2 (T-cell specific. HMG-box) 18,329 7 1.53E-02 0.96 0.77
A_23_P45831 CHD1L chromodomain helicase DNA binding protein 1-like 19,187 1,428 1.94E-02 0.98 0.93
A_23_P48175 TMEM106C transmembrane protein 106C 18,096 410 2.00E-02 0.96 0.88
A_23_P39251 PLIN5 perilipin 5 229 17,725 2.16E-02 1.34 1.05
A_23_P200780 TGFBR3 transforming growth factor. beta receptor III 17,259 94 2.47E-02 0.94 0.80
A_23_P110791 CSF1R colony stimulating factor 1 receptor 16,516 49 3.23E-02 0.95 0.80
A_32_P140475 KIAA1377 KIAA1377 72 16,014 3.93E-02 0.82 0.97
A_23_P213620 PPP2R2B protein phosphatase 2. regulatory subunit B. beta 16,049 256 4.14E-02 0.94 0.86
A_32_P75141 15,969 240 4.24E-02 0.94 0.85
A_23_P385105 PLCD4 phospholipase C. delta 4 15,930 354 4.48E-02 0.94 0.86
A_24_P88763 LOXL3 lysyl oxidase-like 3 15,979 413 4.50E-02 0.95 0.89
A_24_P9883 DKFZp761E198 DKFZp761E198 protein 27 15,524 4.61E-02 1.49 1.05
A_23_P109171 BFSP1 beaded filament structural protein 1. filensin 15,892 481 4.75E-02 0.93 0.84
Table 2.  Expression probes and DEGs ranked by significance of sex specificity.
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6%) and 12,338 in females and males, respectively, in EPIC Italy. As regards the 3 male-specific transcriptomic 
signals, all 3 in NSHDS and 2 out of 3 in EPIC ranked higher in males.
The observation that almost all sex-specific features identified show higher sensitivity in females is striking. 
For comparison it is noted that only 116 of the 350 transcripts and 1,009 of the 1,273 CpGs differentially modified 
by smoking in the mixed population have lower FDR values in females. Although, as stated above, the rank-based 
comparison we employed is not expected to be significantly affected by group size, in view of the larger number 
of females in our study (320 female versus 134 male current and never smokers), we ran the same analysis as 
described above 10 times, in each case using all 134 male subjects and an equal number of females sampled 
randomly from our population while maintaining constant the proportions of subjects coming from each of the 
two cohorts and with the different types of smoking status (see Fig. 1, right). In each such resampling analysis, 
the resulting sex-specific epigenetic or transcriptomic signals included on average 50.3% (S.D. 7.3%) and 50.8% 
(S.D. 14.2%) of the signals shown in Tables 2 and 3, respectively, while the cumulative % overlap (average of each 
successive resampling round plus all preceding ones) for both lists tended towards approx. 50%, reflecting the 
similar loss of statistical power of the smaller subpopulations employed (Suppl. Table S3 and Suppl. Fig. S2). These 
observations provide confirmation that the identification of the sex-specific signals was not subject to bias by the 
group size of each sex class.
Discussion
A number of recent studies on smoking-induced changes in methylation profiles, which employed effect size as 
the response classification parameter, failed to detect any sex-specific responses11,12, possibly because of resid-
ual confounding arising from insufficiently accurate adjustment for tobacco smoke exposure. By comparing in 
sex-stratified analyses the significance ranking of transcriptomic and epigenetic signals previously shown to differ 
between current and never smokers in a mixed-sex population, we identified a number of features which exhibit 
significantly different responses in the two sexes. Because the highly stringent nature of our non-parametric, 
rank-based statistical methodology inevitably attenuates sensitivity, it is possible that additional features with 
sex-specific behaviour may exist. On the other hand this approach has the advantage that it minimizes false pos-
itive findings and maximizes specificity.
Our observation that almost all features identified show stronger responses in females implies the possibil-
ity of higher female susceptibility to diseases related to the corresponding genes. The most notable observa-
tion regarding the list of sex-specific DEGs and DMGs relates to the presence of multiple genes related to CVD, 
especially genes involved in thrombin signaling and vascular and endothelial cell function. Table 4 summarises 
the relevant evidence (discussed further below) and compares the changes observed in the present study with 
those reported in clinical studies, where such information is available. It can be seen that the direction of change 
reported in these studies is in concordance with that which we have observed in apparently healthy female smok-
ers, supporting the relevance of these changes to disease pathogenesis.
Genes involved in thrombin signaling. Thrombin, a serine protease, has an essential role in coagu-
lation and haemostasis mediated by platelets, while in addition it elicits important effects in endothelial and 
vascular smooth muscle cells (VSMC). For these reasons thrombin-mediated effects are of great importance 
in the pathogenesis of CVD. Most of the cellular effects of thrombin are initiated via the activation of a family 
of G-protein-coupled receptors called protease-activated receptors (PARs), which are transmembrane proteins 
expressed on different types of cells including platelets, endothelial cells and VSMC. The main thrombin receptor 
on platelets and blood vessel cells is PAR1, also known as coagulation factor II (thrombin) receptor (F2R). This 
gene plays a key role in vascular function and CVD13 and its genetic variants are known to influence platelet 
function14,15. In our previously published analysis of the effects of smoking on transcriptomic and epigenetic 
profiles10 we found F2R to be differentially underexpressed in current smokers with a statistical significance of 
FDR = 0.15 which just fails to reach the threshold adopted in the present analysis (FDR < 0.10). Inclusion of 
the F2R-related expression probe together with the 350 probes with FDR < 0.10 in the sex-stratified analysis 
described above reveals a highly significant female specificity of the effect of smoking on this gene. Thus, in male- 
and female-stratified analyses, respectively, the significance rankings for current-versus-never-smoker compar-
isons were 29,197 and 1,283 (p = 1.08 × 10−4), the FDR values 0.98 and 0.040 and the effect sizes 1.00 and 0.88.
The interaction of thrombin with PAR1 in platelets is facilitated by its initial binding to the GPIb-IX-V com-
plex which plays a critical role in thrombosis, atherogenesis and inflammation16. This complex includes the glyco-
protein GP5, which is associated with a CpG site we found to be differentially overmethylated in female smokers 
(Table 3). Following its activation via the cleavage of its N-terminal domain by thrombin, PAR1 initiates multiple 
kinase signaling pathways which lead to different effects depending on the cells concerned (Fig. 2). Such effects 
include hemostasis and thrombosis in the case of platelets, induction of pro-inflammatory phenotype in the case 
of endothelial cells, increase of vascular permeability, proliferation, migration and hypertrophy in the case of 
VSMCs, thus contributing to the pathogenesis of different types of CVD.
Signaling by the activated PAR1 receptor is controlled by, among other factors, Src kinases17, including FYN 
(FYN proto-oncogene, Src family tyrosine kinase) which is associated with a CpG site differentially under-
methylated in female smokers. Following initiation of GPIb-IX-V/PAR1 signalling, FYN phosphorylates PKCδ 
(protein kinase Cδ ) which subsequently negatively modulates platelet activation18. The importance of FYN for 
haemostasis-related disease is underlined by the report that FYN-deficient mice show an altered haemostatic 
response19.
Another gene which influences platelet function is IGF1R (insulin-like growth factor 1 receptor), which is 
associated with a CpG site differentially overmethylated in female smokers. The IFG1R protein is expressed at 
high levels on the plasma membrane of platelets while its ligand, IGF1, is a growth factor found in the α granules 
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Probe
Gene 
symbol Gene name
Rank by p-value in sex-
stratified analysis Males Females
absΔΔβ = abs(Δβfem −
Δβm)Males Females
p rank 
difference
β* current 
smokers
β* never 
smokers Δβm#
β* current 
smokers
β* never 
smokers Δβfem#
cg03378003 SETD2 SET domain containing 2 410,615 375 1.73E-08 84.23 84.24 0.00 84.92 83.59 1.33 1.33
cg05713794 GP5 glycoprotein V (platelet) 399,753 108 4.17E-08 81.42 81.44 − 0.02 80.63 78.46 2.17 2.19
cg13411554 CACNA1D calcium channel. voltage-dependent. L type. alpha 1D subunit 398,828 206 4.53E-08 29.34 29.25 0.08 34.69 28.22 6.47 6.39
cg19028369 C3orf19 chromosome 3 open reading frame 19 395,672 613 6.06E-08 4.45 4.46 − 0.01 4.29 4.59 − 0.29 − 0.29
cg12611488 SKI SKI proto-oncogene 394,498 63 6.38E-08 78.07 77.99 0.08 82.74 78.36 4.39 4.31
cg00436663 LOC400927 388,154 171 1.07E-07 4.89 4.88 0.01 4.58 5.04 − 0.45 − 0.47
cg17993335 DNMBP dynamin binding protein 387,580 886 1.19E-07 79.14 79.20 − 0.06 80.01 78.03 1.99 2.05
cg15743533 FAM110A family with sequence similarity 110. member A 369,751 234 4.50E-07 11.46 11.50 − 0.04 10.67 11.72 − 1.05 − 1.01
cg17098415 366,343 190 5.79E-07 1.83 1.84 − 0.02 1.93 2.20 − 0.27 − 0.25
cg17532753 HDAC4 histone deacetylase 4 370,727 5.606 6.26E-07 67.37 67.24 0.13 67.71 66.06 1.65 1.52
cg25115829 SUZ12P SUZ12 polycomb repressive complex 2 subunit pseudogene 1 179,095 698 7.57E-07 73.04 72.23 0.81 75.55 72.97 2.58 1.77
cg13543915 360,064 247 9.28E-07 61.82 61.91 − 0.09 62.91 64.51 − 1.60 − 1.52
cg09257526 IL6R interleukin 6 receptor 359,954 1.607 1.03E-06 20.44 20.52 − 0.08 20.04 20.67 − 0.62 − 0.55
cg12689529 KIRREL3 kin of IRRE like 3 (Drosophila) 341,191 406 3.63E-06 6.84 6.91 − 0.07 6.50 7.19 − 0.69 − 0.62
cg13379236 EGF epidermal growth factor 332,044 256 6.73E-06 60.43 60.24 0.19 62.51 60.67 1.84 1.65
cg06459104 EPB41L3 erythrocyte membrane protein band 4.1-like 3 331,586 341 6.98E-06 34.31 34.76 − 0.46 33.82 38.07 − 4.25 − 3.79
cg10232140 ERCC6 excision repair cross-complementation group 6 328,904 141 8.25E-06 1.54 1.50 0.05 1.78 1.32 0.46 0.41
cg27430293 152,757 2.427 8.33E-06 34.11 33.26 0.85 36.95 34.92 2.03 1.18
cg04985185 MBTPS1 membrane-bound transcription factor peptidase. site 1 321,636 229 1.34E-05 83.83 83.59 0.24 84.90 82.76 2.14 1.89
cg27171474 CDCA8 cell division cycle associated 8 329,032 404 2.05E-05 84.89 84.78 0.11 86.22 85.01 1.21 1.09
cg08202265 TAC1 tachykinin. precursor 1 314,885 272 2.09E-05 87.55 87.23 0.31 88.45 85.15 3.30 2.99
cg08528970 311,563 11.616 5.23E-05 13.11 13.34 − 0.22 13.88 14.30 − 0.41 − 0.19
cg02003183 CDC42BPB CDC42 binding protein kinase beta (DMPK-like) 296,555 442 6.59E-05 8.34 8.14 0.21 6.33 5.57 0.76 0.55
cg10665960 EPC2 enhancer of polycomb homolog 2 295,295 491 7.13E-05 4.71 4.66 0.05 4.57 4.90 − 0.33 − 0.38
cg26724967 IL32 interleukin 32 184,670 577 9.65E-05 59.76 60.34 − 0.58 59.95 61.77 − 1.82 − 1.25
cg07411111 TPD52L2 tumor protein D52-like 2 289,518 998 1.04E-04 61.46 61.04 0.42 62.07 59.99 2.08 1.66
cg09374353 EHD1 EH-domain containing 1 284,155 321 1.36E-04 20.73 20.54 0.19 18.44 19.61 − 1.18 − 1.37
cg23670519 278,212 616 1.94E-04 27.86 27.27 0.59 27.09 24.35 2.74 2.15
cg05307957 ARID1A AT rich interactive domain 1A (SWI-like) 277,497 132 1.97E-04 2.70 2.78 − 0.08 2.99 3.38 − 0.39 − 0.31
cg20305005 SCN2A sodium channel. voltage-gated. type II. alpha subunit 273,040 240 2.54E-04 58.37 57.96 0.42 58.65 56.27 2.38 1.96
cg13989999 BCL2L1 BCL2-like 1 268,258 3.290 3.89E-04 47.52 47.93 − 0.41 48.03 49.34 − 1.31 − 0.90
cg06397161 SYNGR1 synaptogyrin 1 262,200 1.787 4.96E-04 42.48 42.79 − 0.31 44.56 46.19 − 1.63 − 1.32
cg06959021 TCHP trichoplein. keratin filament binding 255,728 173 6.39E-04 58.68 58.28 0.40 61.71 59.85 1.86 1.45
cg01911191 253,223 1.609 7.82E-04 2.70 2.62 0.08 2.34 2.07 0.27 0.19
cg25446789 DTNB dystrobrevin. beta 150,180 257 8.25E-04 40.28 40.87 − 0.60 40.07 42.21 − 2.14 − 1.55
cg14179401 249,065 983 9.35E-04 33.38 33.60 − 0.22 34.75 35.82 − 1.07 − 0.85
cg08601457 FYN FYN proto-oncogene. Src family tyrosine kinase 242,282 422 1.27E-03 7.11 7.28 − 0.17 5.98 6.68 − 0.70 − 0.53
cg16702313 C14orf43 chromosome 14 open reading frame 43 239,378 153 1.45E-03 60.71 61.00 − 0.29 61.85 63.45 − 1.60 − 1.31
cg13832372 LHX6 LIM homeobox 6 239,227 188 1.46E-03 10.96 11.42 − 0.45 10.32 12.60 − 2.28 − 1.83
cg24242519 FAM49A family with sequence similarity 49. member A 236,302 1.218 1.77E-03 13.47 13.75 − 0.28 13.51 14.61 − 1.10 − 0.82
cg22638542 SEC22C SEC22 homolog C. vesicle trafficking protein 227,163 329 2.60E-03 80.69 80.38 0.31 82.48 81.37 1.11 0.80
cg01904243 C14orf43 chromosome 14 open reading frame 43 225,047 164 2.84E-03 13.97 14.22 − 0.25 12.62 13.82 − 1.20 − 0.95
cg06338710 GFI1 growth factor independent 1 transcription repressor 224,461 205 2.92E-03 76.24 76.90 − 0.66 77.50 79.53 − 2.03 − 1.38
cg19048950 LOC100188 219,307 463 3.72E-03 76.17 75.70 0.46 73.42 71.15 2.28 1.81
cg02104700 S100P S100 calcium binding protein P 217,731 496 4.00E-03 2.42 2.49 − 0.07 2.45 2.67 − 0.22 − 0.15
cg15417641 CACNA1D calcium channel. voltage-dependent. L type. alpha 1D subunit 215,584 77 4.31E-03 50.18 48.86 1.32 53.39 46.64 6.76 5.44
cg11222173 RPTOR regulatory associated protein of MTOR. complex 1 216,169 1.025 4.38E-03 62.03 61.49 0.54 61.00 58.74 2.26 1.71
cg08062087 C2orf66 chromosome 2 open reading frame 66 215,666 587 4.39E-03 69.15 68.61 0.54 70.09 68.06 2.03 1.49
cg14950321 PLIN5 perilipin 5 215,623 763 4.44E-03 39.87 40.42 − 0.55 41.31 43.13 − 1.82 − 1.27
cg08778287 IGF1R insulin-like growth factor 1 receptor 214,383 476 4.62E-03 33.41 32.78 0.64 31.37 28.84 2.54 1.90
cg13698937 C4orf46 chromosome 4 open reading frame 46 210,788 694 5.45E-03 76.64 75.97 0.67 77.47 75.32 2.15 1.49
cg00357551 FAM196B family with sequence similarity 196. member B 207,522 1.016 6.33E-03 33.01 32.52 0.50 32.30 30.79 1.51 1.01
cg04359840 XYLT1 xylosyltransferase I 206,167 346 6.52E-03 47.27 47.85 − 0.58 47.80 49.99 − 2.19 − 1.61
cg21698310 PPP1R9B protein phosphatase 1. regulatory subunit 15A 203,847 822 7.32E-03 10.66 10.89 − 0.23 9.69 10.49 − 0.81 − 0.58
cg00816037 FAM38A family with sequence similarity 38. member A 197,944 281 9.10E-03 7.77 8.09 − 0.33 6.69 7.77 − 1.08 − 0.75
cg24488469 192,915 314 1.11E-02 15.97 16.30 − 0.33 14.06 15.16 − 1.09 − 0.76
cg12033822 SLC35C2 solute carrier family 35 (GDP-fucose transporter). member C2 189,184 1.519 1.34E-02 26.76 27.15 − 0.40 25.56 26.54 − 0.98 − 0.58
Continued
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in platelets. Stimulation of platelets with IGF1 results in rapid phosphorylation of IGF1R and potentiation of 
PAR1-induced platelet aggregation20.
As already mentioned, thrombin-mediated PAR (including PAR1) signaling also operates in VSMC and 
endothelial cells, thereby playing an important role in diverse cellular activities related to inflammation, CVD, 
tumor growth and other conditions. In this context the genes discussed above (with the exception of GP5 which 
is expressed only in platelets) can be anticipated to affect by analogous mechanisms the pathogenesis of such 
diseases. Moreover, a number of additional genes of relevance to thrombin signaling in VSMC and endothelial 
cells is included in the list of genes found to be differentially modified in female smokers. One of these genes is 
EGF (epidermal growth factor), differentially overmethylated in female smokers, a potent mitogenic factor in 
many cell types acting through its receptor EGFR. Activation of EGFR promotes thrombin-induced prolifera-
tion of VSMC21, while its inhibition attenuates thrombin-stimulated signalling along the PI3K-Akt-mTOR-S6K1 
axis, leading to effects on cell proliferation and motility22. Importantly, EGFR signalling is coordinated by EPS8 
(epidermal growth factor receptor pathway substrate 8)23, which is underexpressed in female smokers. In support 
of a probable role of EPS8 in vascular disease is the report that EPS8-null mice show increased vascular perme-
ability24. Finally, RPTOR (regulatory associated protein of MTOR, complex 1), overmethylated at 2 CpG sites in 
female smokers, negatively regulates mTOR kinase25 which, as mentioned above, is involved in thrombin signa-
ling in VSMC. It is noted that mice with an RPTOR deletion targeted on the myocardium have been reported to 
develop dilated cardiomyopathy26.
Other genes related to CVD pathogenesis. The list of genes exhibiting sex-specific response to tobacco 
smoking includes a number of additional members for which there is significant clinical or mechanistic evidence, 
Probe
Gene 
symbol Gene name
Rank by p-value in sex-
stratified analysis Males Females
absΔΔβ = abs(Δβfem −
Δβm)Males Females
p rank 
difference
β* current 
smokers
β* never 
smokers Δβm#
β* current 
smokers
β* never 
smokers Δβfem#
cg22490254 186,085 396 1.45E-02 15.92 15.44 0.48 15.51 13.87 1.64 1.16
cg26840970 ZNF19 zinc finger protein 19 315,231 309 1.54E-02 69.05 68.76 0.29 71.08 68.75 2.33 2.04
cg09608073 CHSY3 chondroitin sulfate synthase 3 184,657 712 1.55E-02 9.31 9.50 − 0.19 7.99 8.47 − 0.48 − 0.29
cg19925780 179,222 134 1.85E-02 57.36 56.05 1.30 59.58 56.04 3.54 2.24
cg25223634 C10orf26 chromosome 10 open reading frame 26 172,484 368 1.90E-02 37.56 38.21 − 0.64 35.14 37.58 − 2.43 − 1.79
cg00026474 ST3GAL1 ST3 beta-galactoside alpha-2.3-sialyltransferase 1 178,373 842 1.96E-02 19.10 19.54 − 0.44 19.23 20.63 − 1.40 − 0.96
cg25114611 FKBP5 FK506 binding protein 5 362,777 198 1.97E-02 30.27 30.36 − 0.08 30.44 31.81 − 1.37 − 1.28
cg01609214 MIR30D microRNA 30d 174,169 418 2.24E-02 89.84 89.03 0.81 90.88 87.38 3.50 2.69
cg21188533 CACNA1D calcium channel. voltage-dependent. L type. alpha 1D subunit 173,743 61 2.24E-02 43.74 41.82 1.91 52.19 43.74 8.45 6.54
cg06627354 TRPM8 transient receptor potential cation channel. subfamily M. member 8 173,046 285 2.32E-02 65.91 65.21 0.70 64.45 61.66 2.79 2.10
cg25722983 STK40 serine/threonine kinase 40 290,462 740 2.36E-02 45.26 45.55 − 0.29 46.40 47.91 − 1.52 − 1.22
cg25233339 ATP1B3 ATPase. Na+ /K+ transporting. beta 3 polypeptide 250,770 212 2.37E-02 3.69 3.79 − 0.10 3.03 3.48 − 0.45 − 0.35
cg00449189 171,418 702 2.49E-02 12.06 12.39 − 0.33 10.75 11.51 − 0.77 − 0.44
cg08287903 UGT8 UDP glycosyltransferase 8 169,875 180 2.58E-02 48.84 48.15 0.69 51.00 48.24 2.76 2.06
cg05055821 168,762 322 2.69E-02 9.90 9.65 0.26 9.44 8.67 0.77 0.52
cg05525812 171,414 3.675 2.76E-02 16.95 17.39 − 0.44 15.71 16.55 − 0.84 − 0.40
cg20530056 IKBKE inhibitor of kappa light polypeptide gene enhancer in B-cells. kinase epsilon 168,953 1.699 2.80E-02 63.75 64.26 − 0.51 64.64 65.97 − 1.33 − 0.82
cg01963224 166,963 102 2.84E-02 12.83 13.10 − 0.28 11.88 12.94 − 1.06 − 0.78
cg05548393 SLC30A8 solute carrier family 30 (zinc transporter). member 8 165,967 483 2.98E-02 77.09 76.22 0.87 78.67 76.30 2.37 1.50
cg24715767 PRDM2 PR domain containing 2. with ZNF domain 165,652 337 3.00E-02 57.80 57.13 0.67 61.48 59.19 2.29 1.62
cg05603910 ANO9 anoctamin 9 167,628 3.304 3.10E-02 78.58 77.55 1.03 75.77 73.98 1.79 0.77
cg16660971 RPTOR regulatory associated protein of MTOR. complex 1 163,969 323 3.17E-02 72.09 71.01 1.08 71.01 66.95 4.06 2.98
cg06361984 NDE1 nudE neurodevelopment protein 1 159,841 809 3.69E-02 82.89 82.22 0.67 81.19 79.42 1.77 1.10
cg17873451 LOC440925 157,993 231 3.84E-02 4.11 4.26 − 0.15 3.54 3.90 − 0.37 − 0.22
cg03220447 NAV2 neuron navigator 2 159,803 2.277 3.87E-02 12.43 12.70 − 0.27 12.44 12.97 − 0.53 − 0.26
cg05756780 IL6R interleukin 6 receptor 156,614 1.147 4.13E-02 23.32 23.63 − 0.31 22.65 23.65 − 1.00 − 0.69
cg02104644 SYT7 synaptotagmin VII 158,677 4.255 4.27E-02 19.47 20.07 − 0.59 18.63 19.87 − 1.24 − 0.64
cg08242636 CBFB core-binding factor. beta subunit 155,174 1.149 4.33E-02 5.10 5.25 − 0.15 5.00 5.37 − 0.37 − 0.22
cg22006825 HNRNPUL1 heterogeneous nuclear ribonucleoprotein U-like 1 171,009 17.624 4.41E-02 19.13 19.57 − 0.45 19.20 19.75 − 0.55 − 0.10
cg07201017 FLJ41350 LBX1 antisense RNA 1 (head to head) 159,918 6.965 4.48E-02 16.26 16.59 − 0.33 15.82 16.34 − 0.52 − 0.19
cg02571448 PCBP3 poly(rC) binding protein 3 151,595 974 4.81E-02 41.12 41.91 − 0.79 41.66 43.59 − 1.93 − 1.14
cg24968629 CELSR1 cadherin. EGF LAG seven-pass G-type receptor 1 177,517 192 4.85E-02 74.90 73.75 1.15 70.52 65.45 5.07 3.92
cg25474070 IL3 interleukin 3 173,116 895 4.92E-02 62.86 63.34 − 0.47 64.15 65.74 − 1.59 − 1.12
cg19859980 C1orf97 chromosome 1 open reading frame 97 154,094 4.225 4.92E-02 2.51 2.60 − 0.09 2.59 2.74 − 0.15 − 0.06
cg03699074 FAM38A family with sequence similarity 38. member A 150,341 568 4.94E-02 14.23 14.69 − 0.46 12.81 14.07 − 1.26 − 0.79
Table 3.  CpG sites and DMGs ranked by significance of sex specificity. *Methylation level (%); #Δ β = difference 
in % methylation of current-never smokers.
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including evidence from transgenic animal studies, that they are linked with CVD pathogenesis. The gene with 
the largest expression change in female smokers is HMOX1 (haem oxygenase 1), well known for its antioxidant 
and anti-inflammatory properties as well as for its protective role against CVD27–29. HMOX1 is also known to 
protect against smoking-induced COPD30, a disease for which there is strong evidence of differentially higher 
susceptibility in female smokers1,5,6. Another gene of interest is HDAC4 (histone deacetylase 4), differentially 
overmethylated in female smokers, which plays a global role in the epigenetic control of gene expression by 
modifying histones as well as non-histone proteins31 and plays an important role in regulating hypertrophic 
responses32. Finally of particular note is the female-specific demethylation of the well known anti-apoptotic gene 
BCL2L1 (BCL2-like 1), which plays a key role in the regulation of platelet activation and apoptosis33. Among the 
consequences of platelet apoptosis is the production of microparticles, which are recognised to play an important 
role in inflammation, CVD, coagulation and angiogenesis34.
The largest sex-related difference in the impact of smoking (absΔ Δ β , last column in Table 4) is observed at 
3 CpG sites associated with CACNA1D (calcium channel, voltage-dependent, L type, alpha 1D subunit). This 
gene encodes for the cav1.3 subunit of a voltage-gated, L-type calcium channel and human and animal studies 
strongly support its association with various pathological conditions, including cardiovascular and neurological 
disorders35–38. On a side note, it is of interest that cav1.3 physically interacts with the receptor of GABAB, with 
activation of the latter leading to an increase in the L-type calcium channel currents39. Given the key role of this 
receptor in the mechanism of addiction, it is possible that any sex-related variation in CACNA1D expression 
may be reflected in corresponding differences in susceptibility to nicotine addiction. In support of this idea, sev-
eral lines of evidence indicate that females have a higher susceptibility to nicotine dependence, including faster 
progression to dependence, shorter and less frequent abstinence periods, greater difficulty to quit, and poorer 
response to smoking cessation treatments38,40,41.
Other genes listed in Table 4, for which there is evidence of varying strength of links with different types of 
CVD, include TAGLN (transgelin42), SYNE1 (spectrin repeat containing, nuclear envelope 1)43,44, IL32 (inter-
leukin 32)45, PLIN5 (perilipin 5)46, HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U-Like 1)47 and 
miR-30d48. Finally, Table 4 shows a number of genes (C14orf43, C1orf21, ST3GAL1 and ZNF19) which do not 
Gene
Direct evidence of links with 
CVD pathogenesis
Mechanistic 
basis of links 
with CVD
Current study
Vasclular 
inflam-
mation28
Chronic 
artery 
occlussion48
Myocardial 
infarction63
Coronary 
heart 
disease64
Coronary 
artery 
disease65
Peripheral 
arterial 
disease66
Myocardial 
infarction67
Venous 
thrombo-
embolism68
Atherosus-
ceptibility69
expr* meth# expr* expr* expr* expr* expr* expr* expr* expr* meth#
F2R (PAR1) polymorphisms in human CVD14
thrombin 
signaling/
vascular 
haemostasis
down down down
GP5 up
FYN transgenic mice19 down up
IGF1R up up
EGF up
EPS8 transgenic mice24 up
RPTOR transgenic mice26 up
HMOX1
polymorphisms and differential 
expression in human CVD28; 
transgenic mice28
anti-
inflammatory down down
HDAC4 regulation of hypertrophy
BCL2L1 anti-apoptotic down up
CACNA1D polymorphisms in human CVD
37; 
transgenic mice35,36
calcium 
signalling up
TANGLN polymorphisms in human CVD
70; 
transgenic mice42 VSMC/
endothelial cell 
function
down
SYNE1 polymorphisms in human CVD
37; 
transgenic mice35,36 down down
IL32 differential expression in human CVD45; transgenic mice45
pro-
inflammatory down
PLIN5 transgenic mice46 oxidative stress down
HNRNPUL1 polymorphisms in human CVD47 unknown down
miR-30d differential expression in human CVD48
regulation of 
cardiomyocyte 
apoptosis71
up up down
C14orf43 differential expression in human CVD61 unknown down down
C1orf21 differential expression in human CVD59 unknown down down
ST3GAL1 differential expression in human CVD59 unknown down up
ZNF19 differential expression in human CVD59 unknown up down
Table 4.  Female-specific DEGs/DMGs of potential relevance to CVD. and their expression/methylation 
changes observed in present study or reported clinical studies (where available). The genes are listed in the 
order in which they are discussed in the main text. Col. 1 presents evidence based on human population and 
transgenic animal studies. *Expression; #methylation.
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have any function related to CVD pathogenesis, however they have been reported to be differentially expressed 
in patients with different types of CVD.
Molecular basis of sex-specific effects of tobacco smoke exposure. The previous discussion shows 
that numerous genes among those found to be differentially altered in female smokers interact closely in the con-
text of thrombin signaling in platelets and vascular/endothelial cells. While the molecular basis for such differ-
ential female susceptibility to tobacco smoke is not currently understood, there is strong evidence that thrombin 
signaling and hemostasis are subject to hormonal influences and it is possible that such influences may also mod-
ify the responses to tobacco smoking. Megakaryocytes and platelets express the estrogen and androgen receptors, 
and the coagulation cascade is known to be influenced by variations in the levels of female sex steroids49–51, while 
it has been suggested that females have greater baseline platelet reactivity which may be attenuated by estro-
gens51,52. Furthermore, it has been reported that platelets from women are more responsive than those of men to 
thrombin agonists51, and that females with atherosclerosis show higher PAR1-mediated platelet activation53. Sex 
hormones contribute to the modulation of additional genes related to CVD and may therefore also modify the 
impact of smoking. For example, the expression of HMOX1 under conditions of oxidative stress is modulated by 
estrogen receptor alpha54, while estrogen receptor beta modulates the expression of HDAC4 under the influence 
of hypertrophic factors in rat cardiomyocytes55.
Summarising the preceding discussion, a large number of genes which are known or suspected to play a role 
in the mechanism of CVD, and to modulate corresponding disease risks, have their expression or methylation in 
WBCs modified by smoking significantly more in females than in males. It is not known whether similar changes 
occur in other tissues of smokers. However we have recently reported that tobacco smoking causes similar 
changes in expression and CpG methylation in the Ah receptor repressor gene in WBCs and lung cells10. We have 
also shown that the genes which are differentially expressed or methylated in WBCs of smokers are closely related 
to many smoking-induced diseases regardless of their target tissue, implying that changes observed in blood cells 
may reflect more global effects. This conclusion is further supported by the concordance of the results presented 
in the present study with the conclusions of epidemiological studies which consistently point to a higher female 
susceptibility to tobacco-induced CVD. Furthermore, we also report analogous, although more limited, findings 
supporting higher female susceptibility to tobacco-induced COPD and nicotine addiction. Although our evalua-
tion of the disease-relevance of the sex-specific DEGs and DMGs presented above did not include cancer, many of 
the signaling pathways discussed are also highly relevant to carcinogenesis56. It is noted that the current evidence 
regarding sex susceptibility to tobacco-related cancer is mixed7–9,57.
In conclusion, the results presented here underline the utility of blood-based omics profiling for identifying 
health hazards associated with environmental exposures and suggest a potential for use of such data in identifi-
cation of susceptible sub-groups.
Materials and Methods
The present report is based on data from the Envirogenomarkers project (www.envirogenomarkers.net). 
Envirogenomarkers is a prospective case-control study nested within the European Prospective Investigation into 
Cancer and Nutrition study (EPIC-ITALY) and the Northern Sweden Health and Disease Study (NSHDS)58,59, 
in which subjects asymptomatic at the time of enrolment provided a blood sample and information on dietary 
habits, lifestyle, health history etc. The EnviroGenomarkers project and its associated studies and experimental 
protocols were approved by the Regional Ethical Review Board of the Umea Division of Medical Research, for the 
Figure 2. Schematic representation of some of the interactions involved in PAR1 signalling initiated by 
thrombin. All genes shown, are preferentially modified in female smokers, PAR1 being differentially expressed 
and the others differentially methylated. The genes shown near the arrow participate in signalling downstream 
of PAR1 and the order in which they are shown does not imply a sequential interaction.
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Swedish cohort, and the Florence Health Unit Local Ethical Committee, for the Italian cohort, and all participants 
gave written informed consent. All methods were carried out in accordance with the approved guidelines.
Owing to the Envirogenomarkers project’s design, some of the participating subjects had been selected on 
the basis of the fact that they went on to develop breast cancer or B-cell lymphoma 2–16 years after recruitment, 
however for the purposes of the present study they were all treated as apparently healthy. We have previously 
shown that inclusion of such subjects did not significantly affect the list of smoking-modified transcriptomic 
and epigenetic features10. Anthropometric measurements and lifestyle parameters had been collected through 
questionnaires at recruitment (1993–1998 for EPIC-ITALY; 1990–2006 for NSHDS). Information on smoking 
was obtained through questionnaires and included data on duration, number of cigarettes smoked per day and 
(only in Italy) pack-years. In addition, for a fraction of the subjects data on plasma cotinine concentration were 
also available. Details of the subjects involved in the present study are shown in Table 1. Sample collection, storage 
and processing procedures have been described elsewhere58,59. Based on the conclusions of a previously published 
pilot study60, subjects were included in the study only if the processing of their blood samples and placement of 
their buffy coats in cold storage had been completed within 2 hours of collection so as to minimize effects on the 
transcriptomic profile.
RNA and DNA extraction from buffy coats, genome-wide analysis of gene expression (Agilent 4 × 44 K 
human whole genome microarray platform) and CpG methylation (Illumina Infinium HumanMethylation450 
platform) and the corresponding data quality assessment and preprocessing, were conducted as described previ-
ously60. Cotinine levels (AUC) in plasma were measured by reverse-phase chromatography on an Acquity UPLC 
system (Waters Corporation, Milford, MA, USA) with a Acquity HSS T3 C18 10 mm × 2.1 mm, 1.8 μ m, column 
(Waters) and a binary gradient elution comprising of water 0.1% formic acid and acetonitrile 0.1% formic acid 
for 19 min. Online analysis of the eluent was performed using a quadrupole time-of-flight mass spectrometer 
(QTOF-Ultima-MS; Waters) in the positive ion mode. Data were processed using Databridge and XCMS software 
(Waters). We confirmed the identity of cotinine with authentic standard and accurate mass.
Data analysis and the derivation of lists of expression probes and CpG sites which differed significantly 
between current and never smokers has been described in detail previously10. Briefly, linear mixed models 
were ran, using M values for DNA methylation or log2 intensities of mRNA expression as dependent variables, 
plus date of isolation, labeling, and hybridization for RNA expression, or date of analysis for methylation, as 
random variables. All analyses additionally adjusted for sex, age, BMI and cohort. Owing to the design of the 
EnviroGenomarkers project, future disease (breast cancer, B-cell lymphoma) and case-control status were also 
included as fixed variables. In the case of DNA methylation data, the models were also adjusted for blood cell 
composition estimated with a published algorithm61. Multiple testing was accounted for with high stringency 
by using Bonferroni or FDR Benjamini-Hochberg correction. This procedure led to the identification of lists, 
recently published10, of 1,273 CpG sites (FDR < 0.05) and 350 transcripts (FDR < 0.10) which differ significantly 
in current relative to never smokers (Suppl. Tables 1 and 2).
We looked for sex-related differences among the above mentioned expression and DNA methylation features 
by employing rank-based, non-parametric, statistical testing methodology based on the evaluation of the dif-
ferences in the significance ranks of the probes in the two classes (Fig. 2). Towards this end we first conducted 
current-versus-never smoker comparisons, using the same statistical models as previously, for all transcriptomic and 
epigenetic features (29,667 expression probes and 410,987 methylation probes, respectively) separately in males and 
females, ranking all features by the corresponding significance (p-value). Subsequently we extracted from these lists 
the rank values of the features which we had previously found to be significant in the mixed population (350 expres-
sion probes significant at FDR < 0.10 and 1,273 CpGs significant at Bonferoni-corrected p < 0.05) and calculated 
their differences between the two sexes. We thus derived a distribution of differences which conforms to the normal-
ity assumption (steep unimodal) and was used as basis in order search for differences that violate the null hypothesis 
that only non-sex-related differences are observed, i.e. signal rankings in sex-stratified analyses are equal. The statis-
tic was calculated from the corresponding complementary cumulative distribution function (Survival Function)62 
which describes the probability that a variate takes a value greater than a particular number, taking as a significance 
threshold the value of p < 0.05. The workflow of this analysis is described diagrammatically in Fig. 1. The tool for the 
implementation of the statistical evaluation of sex-specific rank differences described above is publically available, 
under the name RIPOSTE (“Rank DrIven POpulation STatistical Evaluation”), on the Galaxy platform at http://
mebioinfo.ekt.gr/galaxy, where instructions for its use are also given.
In order to check for any bias introduced by the difference in male and female population sizes on the selection 
of sex-specific signals, we implemented a permutation probabilistic approach (also illustrated in Fig. 1, right) 
by randomly resampling 10 times the full population so as to extract subpopulations even with respect to sex 
and smoking status, subsequently applying to all subpopulations thus selected the same analytical workflow as 
described above. In each subpopulation we used all available male subjects (134) and an equal number of females 
selected randomly while maintaining unaltered the proportions of females from the different cohorts and with dif-
ferent smoking status. For each resampling we counted the number of significant (p < 0.05 for rank difference) 
signals that came from among those obtained with the full male and female populations (shown in Tables 2 and 3).
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